MorphoSys and Incyte Presents Five-Year P-II Study (L-MIND) Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma AACR 2023
Shots:
- The P-II study evaluating tafasitamab + lenalidomide in 81 patients who had one but no more than 3 prior lines of therapy, incl. an anti-CD20 targeting therapy who were not eligible for high-dose CT or refused subsequent autologous SCT
- At data cut-off of Nov 2022, the therapy showed ORR (57.5%), CR (41.2%); PR (16.2%) & additional results incl. mDoR (not reached) after a median follow-up of 44.0mos., m-OS (33.5mos.) & m-PFS (11.6mos.). Among 21 patients with >60mos. of follow-up, 14 had received 1 prior line of therapy (pLoT) & 7 with ≥2 pLoT
- Patients achieved higher ORR (67.5%) with 1 pLoT (CR = 52.5% & PR = 15%) vs 47.5% with 2 pLoT (CR = 30% & PR = 17.5%) with no new safety signals, patients experienced a lower frequency of all-grade & grade ≥3 AEs during monotx.
Ref: morphosys | Image: morphosys
Related News:- MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
